Navigation Links
Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
Date:6/22/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results of a 52-week phase III clinical trial of the investigational agent empagliflozin*, which showed statistically significant reductions in HbA1c (average blood glucose) at week 24 with the addition of empagliflozin to existing oral antihyperglycemic therapy in adults with type 2 diabetes (T2D) and mild to moderate kidney impairment (eGFR>/=60 to <90 ml/min/1.73 m2 and eGFR>/=30 to <60 ml/min/1.73 m2).1

Empagliflozin is a member of the sodium glucose co-transporter-2 (SGLT2) inhibitor class of compounds, and is being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption by the kidney.

Results from the study, presented at the American Diabetes Association 73rd Scientific Sessions®, also demonstrated a significant reduction in body weight and blood pressure with empagliflozin versus placebo in patients with mild to moderate kidney impairment.1 Adverse events (AEs) were reported in 79.6 percent, 75.4 percent and 72.7 percent of patients at 24 weeks with empagliflozin 10 mg, empagliflozin 25 mg and placebo, respectively.

"We are encouraged by the data from this phase III study," said Christophe Arbet-Engels, MD, PhD, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Many people with type 2 diabetes also are impacted by renal impairment. Through the Boehringer Ingelheim and Lilly Diabetes alliance, we are using our collective knowledge to find
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
2. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
3. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
4. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
6. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
7. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
8. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
9. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
10. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
11. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- AMETEK, Inc. (NYSE: AME ) today announced ... Vice President and General Manager, Engineered Medical Components, within ... "I am pleased that Kurt has joined AMETEK. ... especially in the medical device industry, and we expect ... and success of our medical components businesses," commented ...
(Date:7/25/2014)... 2014 Leading events organizer UBM Live ... the seventh year to São Paulo, Brazil ... 2014. The event will co-locate with Food Ingredients South America ... meeting point for the pharmaceutical industry.      (Logo: ... pharmaceutical sales are now exploring the South America ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. ... provide a corporate update and report second quarter 2014 ... on Friday, August 1, 2014. That same day, Arena ... a.m. Eastern Time (5:30 a.m. Pacific Time). ... 877.643.7155 for domestic callers and 914.495.8552 for international callers. ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... Jan. 19, 2011 On February 1, 2011, the ... Center for Biomedical Innovation, and Engineering Systems Division will ... Systems Thinking from Discovery to Delivery ... day-long event, sponsored by Merrimack Pharmaceuticals, will be a ...
... RFID Journal features MEPS Real Time,s ... live or die depending on the correct medications being ... tracking of a drug,s expiration dates, information about the ... in REAL TIME, would assist in preventing errors. ...
Cached Medicine Technology:Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 2Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 3Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 4Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 5Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 6Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 7Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 8MEPS Real Time's New RFID Drug Management System Provides Critical Error Solution for California Hospital 2
(Date:7/25/2014)... The European liquid chromatography reagents report ... analysis and forecast of revenue. The liquid chromatography reagents ... in 2013, and is estimated to grow to around ... %, from 2013 to 2018. , Browse through the ... get an idea of the in-depth analysis provided. This ...
(Date:7/25/2014)... Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ... recognizes and attacks invading cancer cells. Tumors protect themselves ... as normal, even while cancer cells are dividing and ... review article published this week in WIREs Nanomedicine ... ability to fight tumors. Nanoparticles are too small ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 The American ... new volunteer network “ABTA CommYOUnity™” during its annual patient ... pivotal time for the brain tumor community as we ... patient and caregiver support services and funding brain tumor ... are passionate about brain tumor awareness and getting our ...
(Date:7/25/2014)... 2014 The North America Artificial lift market ... America with analysis and forecast of revenue. The artificial lift ... $4.7 billion in 2013 to around $7 billion by 2018, ... , Browse through the TOC of North America artificial lift ... This also provides a glimpse of the segmentation in North ...
(Date:7/25/2014)... July 25, 2014 Agoura Hills dentist ... on Zoom Whitening. Zoom Whitening is one of the most ... through a dental professional. This light-assisted treatment uses a prescription-strength ... of the tooth to break up stains that are in ... coffee, tea, wine, soft drink and tobacco stains. , ...
Breaking Medicine News(10 mins):Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Scientists test nanoparticle 'alarm clock' to awaken immune systems put to sleep by cancer 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2
... air pollution due to combustion has been proved to cause ... The research was done by Columbia Center for Children’s Environmental ... Columbia University, US. ,The researchers had observed the ... aromatic hydrocarbons (PAH) that can penetrate placenta to affect the ...
... Researchers have found a herb used in traditional Indian ... and insulin levels // in a manner similar to ... a herb called salacia oblonga, which is native to ... to intestinal enzymes that break down carbohydrates in the ...
... can learn certain words. To investigate whether children under age 1 ... another, researchers worked with parents of 52 children who were 9 ... set of 48 picture cards that depicted common objects such as ... The games were performed four times a week for up to ...
... use of the accepted drug Adderall XR for Attention-Deficit ... adverse reports. FDA, the US counterpart of Health Canada ... a press release has asked the parents of children ... to stop the medication for their children. ,Adderall ...
... than intravenous fluids for children who are dehydrated say ... rehydration therapy is recommended for children with mild to ... pediatric emergency medicine physicians do not use this therapy ... injecting the fluid directly into a vein. ,In ...
... Chennai today. The theme for the congress is Prevention of ... will attend the event from 38 countries across the world. ... once in every three years, since the time of its ... of the city is hosting this year’s three-day event ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: